Molecular Pathology, Diagnostics and Therapeutics of Ovarian Cancers

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3404

Special Issue Editor


E-Mail Website
Guest Editor
Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Interests: metastasis

Special Issue Information

Dear Colleagues,

Ovarian cancer is one of the most aggressive malignancies threatening women’s health worldwide. The first-line treatment for advanced ovarian cancer is debulking surgery followed by neoadjuvant chemotherapy. However, most patients would eventually relapse regardless of initial response to the treatment due to chemoresistance and metastasis. Thus, new treatments are urgently needed. This may have a significant impact on the landscape of ovarian cancer treatment and improve overall patient survival.

In this Special Issue, we would like to invite both original research and review articles highlighting recent advances in potential molecular targets, mechanisms of metastasis, chemoresistance and stemness, and immunotherapy therapy (alone or combined with either chemotherapy or targeted therapy) in ovarian cancer.

Prof. Dr. Michelle K.Y. Siu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • targeted therapy
  • combination therapy
  • immune checkpoint blockade
  • small molecule inhibitors
  • tumor microenvironment
  • metastasis
  • treatment resistance
  • stemness

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3912 KiB  
Article
A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
by Jing-Jing Wang, Michelle Kwan-Yee Siu, Yu-Xin Jiang, Thomas Ho-Yin Leung, David Wai Chan, Huo-Gang Wang, Hextan Yuen-Sheung Ngan and Karen Kar-Loen Chan
Biomolecules 2021, 11(12), 1749; https://doi.org/10.3390/biom11121749 - 23 Nov 2021
Cited by 22 | Viewed by 2967
Abstract
Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of [...] Read more.
Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan–Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. Full article
(This article belongs to the Special Issue Molecular Pathology, Diagnostics and Therapeutics of Ovarian Cancers)
Show Figures

Figure 1

Back to TopTop